Zhejiang Huahai Pharmaceutical (600521) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600521 Zhejiang Huahai Pharmaceutical

Watchlist

14.95
-0.62-3.98%

Market Closed Jan 17 15:00 CST

21.93BMarket Cap19.24P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Huahai Pharmaceutical Gets US FDA Approval to Conduct Trials for Asthma Treatment; Shares Down 4%
MT NewswiresJan 17 00:35 ET
Potential Upside For Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) Not Without Risk
Simply Wall StJan 15 23:09 ET
Zhejiang Huahai Pharmaceutical Gets China Nod for Hypertension Drug
MT NewswiresJan 9 23:57 ET
GF Securities Starts Zhejiang Huahai Pharmaceutical at Buy With 21.57 Yuan Price Target
MT NewswiresDec 31, 2024 04:37 ET · Ratings
Chinese Drug Regulator Accepts Huahai Pharma Unit's Application for Adalimumab Injection
MT NewswiresDec 15, 2024 22:52 ET
Huahai Pharmaceutical's Two Drugs Secures Spot in China's National Drug Procurement Program
MT NewswiresDec 15, 2024 22:50 ET

Comments

Moomoo AI

Mar 22, 2024 20:08

Zhejiang Huahai Pharmaceutical's share price drop doesn't align with its EPS growth and revenue increase, hinting at other influencing factors. Last year's performance suggests unresolved issues, and long-term share price weakness could be a negative sign or a potential turnaround for contrarian investors.

Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects

Moomoo AI

Jan 27, 2024 19:00

Analysts are more bearish on Zhejiang Huahai Pharmaceutical's future, reducing revenue and EPS estimates. The downgrade, coupled with high debt, hints at a potential business downturn.

Analysts Just Slashed Their Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) EPS Numbers

Moomoo AI

Dec 26, 2023 22:49

Investors are hesitant to pay more for Zhejiang Huahai Pharmaceutical's stock due to expected limited future growth. The current P/E ratio mirrors these assumptions.

Investors Aren't Buying Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Earnings

Moomoo AI

Oct 13, 2023 22:19

Zhejiang Huahai Pharmaceutical's efficient reinvestment has driven substantial earnings growth. Market fluctuations notwithstanding, the company's management has successfully utilized capital, as evidenced by its higher-than-average ROE.